HELPING THE OTHERS REALIZE THE ADVANTAGES OF ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Section A, individuals will receive different doses and schedules of oral ABBV-744 tablet to determine safe dosing program. Added individuals will probably be enrolled at the determined monotherapy dosign regimen. In Section B, participants will get oral ruxolitinib and ABBV-744 is going to be provided as "add-on" therapy. In Section C, particip